Data From ESMO 2023 Further Define Treatment Paradigm in Advanced Melanoma
Source: OncLive, January 2024
Oncologists reviewed data from clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care.
During a recent OncLive Peer Exchange, expert oncologists reviewed long-term and preliminary data from key clinical trials in the field of melanoma that could add clarity to treatment standards and lead to improved patient care. During their discussion, the panelists paid particular attention to therapies for patients with BRAF-mutated disease and brain metastases. Findings were primarily presented during the European Society for Medical Oncology (ESMO) Congress 2023, which took place from October 20 to 24, 2023, in Madrid, Spain.
BRAF-Mutated Metastatic Melanoma
The panel began the discussion by emphasizing the importance of consistent genetic testing for patients with advanced melanoma, including immunohistochemistry and standardized next-generation sequencing, to identify patients who could be good candidates for a given therapy. Then they dove into updates from clinical trials in the field presented during ESMO 2023, first examining therapies for patients with BRAF-mutated melanoma.